South32 (ASX:S32) shares drop 16%, focus on manganese rail contract

South32 (ASX:S32) shares drop 16%, focus on manganese rail contract

June 24, 2026

SYDNEY, June 24, 2026, 09:03 AEST

South32 Ltd (ASX:S32) starts Wednesday at A$4.14, down 0.24% from Tuesday. Shares are 16.4% under the 52-week high of A$4.95. That 81-cent drop on 4.49 billion shares wipes out close to A$3.6 billion in equity. Market cap sits at A$18.57 billion.

The decline was just under the S&P/ASX 200’s 0.33% move down to 8,787. The ASX cash market was still in pre-open as of the dateline, with usual trading set to start after the opening auction at around 10 a.m. Sydney. June 24 is a standard trading day.

South32 hasn’t put out any new exchange filing since its June 16 substantial-holder notice. In the absence of fresh news from the company, market watchers have looked instead to updates out of rival Exxaro Resources and changes in the logistics cost of getting South African manganese to port for signals on the stock.

Exxaro said road haulage is 37% more expensive than rail, and logistics makes up 43% of FOB costs — that’s what it costs to get ore onto ships. About 46% of its Tshipi Borwa mine’s output still moves by road. Based on those numbers, Tshipi’s total logistics spending runs about 17% over an all-rail scenario. Shifting everything to rail could lower total FOB costs by around 6% before any transition costs. “Can we not put everything on the rail?” Exxaro metals chief Johan Meyer asked analysts. Reuters

That peer estimate suggests a ballpark value for South32’s own logistics setup. The Hotazel Manganese Mines project signed a 10-year deal with Transnet in August, locking in rail and port capacity. Barry Bezuidenhout, South32 operations VP, called the guaranteed slots “vital” for exports. Transnet CEO Michelle Phillips pointed to “reliable and predictable access” for shippers. South32 has not broken out a similar road percentage or potential savings, so the 6% figure does not map straight onto its bottom line. SAnews

South32’s South African manganese mines turned out 500,000 wet metric tonnes in the March quarter, slightly higher than the 476,000 tonnes from a year ago. Total manganese output from both Australia and South Africa came in below Visible Alpha consensus. The company is still focused on cutting costs and improving shipment reliability as it tries to bring volumes back up.

Shares are down, so valuations have some space again. A poll of 15 analysts puts the average price target at A$4.788, about 15.65% higher than where the stock ended Tuesday. There are nine buys, five holds, and a lone sell. The gap between consensus and current price is nearly the same as the stock’s drop from its 52-week high.

But the rail contract isn’t enough to support the whole valuation. Just having allocated capacity won’t fix network issues, and South32 still needs to clear a bigger capital hurdle in Arizona. Estimated costs for the Taylor zinc-lead-silver project jumped from US$2.16 billion to US$3.3 billion, and first output is now expected in the second half of the 2028 financial year. If there’s another delay or a fresh cost bump, it would more than offset smaller logistics gains in manganese.

South32 is set to report June-quarter numbers on July 20, with full-year results coming on August 27. The market will look for the first hard read on year-end manganese shipments and if the weaker share price is matched by stronger cash conversion.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • Pro Medicus steady post-ASX 50 exit with high valuation hurdle
    June 23, 2026, 8:13 PM EDT. Pro Medicus Ltd (ASX: PME) remained steady after its removal from the S&P/ASX 50 index, closing at A$172.93, up 0.08% since Friday. The stock has risen 36% since late May despite the reshuffle. The company's 116x forward fiscal 2026 earnings valuation poses a challenge amid reduced earnings forecasts. Underlying net profit grew 29.7% to A$67.3 million, boosted by a significant unrealised gain on a 4DMedical stake. Pro Medicus secured a five-year, A$16 million renewal with Ohio State University Wexner Medical Center, enhancing recurring revenue prospects. Analysts remain cautious; RBC Capital Markets retains a Sector Perform rating with a A$195 price target. CEO Sam Hupert highlighted a strong revenue outlook from new contracts starting fiscal 2026 and beyond.